Caris Life Sciences
Caris Life Sciences, a leading innovator in the field of precision medicine, is headquartered in the United States, with significant operations across North America and Europe. Founded in 2008, the company has established itself as a key player in the biotechnology industry, focusing on molecular profiling and advanced diagnostics to enhance cancer treatment. Caris Life Sciences offers a range of unique services, including comprehensive genomic profiling and biomarker testing, which empower healthcare providers to tailor therapies to individual patients. The company’s commitment to advancing personalised medicine has garnered recognition, positioning it as a trusted partner in oncology. With a robust portfolio of cutting-edge technologies, Caris Life Sciences continues to drive significant advancements in patient care and treatment outcomes.
DitchCarbon Score
How does Caris Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Caris Life Sciences's score of 28 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Caris Life Sciences's reported carbon emissions
In 2023, Caris Life Sciences reported total carbon emissions of approximately 1,463,000,000 kg CO2e from Scope 1 and 2 combined, alongside a significant Scope 3 emission total of about 4,594,000,000 kg CO2e. This reflects a decrease from 2022, where Scope 1 and 2 emissions were around 1,760,000,000 kg CO2e, and Scope 3 emissions reached approximately 6,680,000,000 kg CO2e. Despite these figures, Caris Life Sciences has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented climate pledges or SBTi (Science Based Targets initiative) commitments indicates a potential area for improvement in their climate strategy. The emissions data is not cascaded from a parent company, and all figures are reported directly from Caris Life Sciences UK Limited. The company operates within a broader industry context that increasingly prioritises sustainability and carbon reduction, suggesting that future commitments may be necessary to align with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | - | - |
| Scope 3 | 6,680,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Caris Life Sciences is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
